Valeant Pharma (VRX), Other Pharma Stocks Weaker as Clinton Op-Ed Discusses Measures on Drug Prices

September 29, 2016 12:01 PM EDT
Get Alerts VRX Hot Sheet
Price: $15.00 -4.03%

Rating Summary:
    11 Buy, 11 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade VRX Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Valeant Pharma (NYSE: VRX), Mallinckrodt (NYSE: MNK), Horizon Pharma (NASDAQ: HZNP), Mylan (NYSE: MYL) and other pharma stocks are weaker possibly as investors read into Hillary Clinton's comments in a NEJM op-ed overnight.

According to Evecore ISI's Umer Raffat, they key paragraph that all biopharma folks would care about:

Second, to directly address rising prescription drug costs, I will work to remove barriers to competition by streamlining approval of high-quality biosimilar and generic drugs. That includes proposals to ensure that drug companies justify their prices, eliminate "pay to delay" practices, and allow Medicare to directly negotiate for better prices. I will also create a new Federal consumer response team charged with identifying excessive price spikes in long-standing, life-saving treatments, and give them effective new tools to respond.

VRX is down 3.9%, MNK is down 3.8%, HZNP is down 2.9% and MYL is down 4.7%.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Trader Talk

Related Entities

Umer Raffat

Comments

old news
sidiji on 2016-09-29 19:22:50
Mark as Spam | Reply to this comment

this is a rehash of the info her campaign put out beginning of September


Add Your Comment